School of Life Sciences, Anhui University, Hefei, 230601, China.
Institute of Physical Science & Information Technology, Anhui University, Hefei, 230601, China.
Pharmacogenomics. 2021 Jan;22(1):27-39. doi: 10.2217/pgs-2020-0068. Epub 2020 Dec 24.
We investigated the effect of gene DNA methylation in the lipid-lowering efficacy of simvastatin. An extreme sampling approach was used to select 211 individuals from the top and bottom 15% of adjusted lipid-lowering response residuals to simvastatin after eight consecutive weeks. DNA methylation was measured before treatment by the MethylTarget bisulfite sequencing method. DNA methylations were negatively associated with baseline high-density lipoprotein cholesterol (HDL-C) and the change in HDL-C after treatment. methylations were also related to the change in triglyceride and HDL-C. Moreover, mean and methylations explain 7.2% of the ΔTC (total cholesterol) and 17.5% of the ΔHDL-C level variability, respectively. DNA methylations at the gene play significant inhibitory effects in the lipid-lowering therapy of simvastatin.
我们研究了基因 DNA 甲基化对辛伐他汀降脂疗效的影响。采用极端抽样方法，从连续 8 周辛伐他汀降脂反应残差的前 15%和后 15%中选择了 211 名个体。在治疗前，采用 MethylTarget 亚硫酸氢盐测序法测量 DNA 甲基化。DNA 甲基化与基线高密度脂蛋白胆固醇（HDL-C）和治疗后 HDL-C 的变化呈负相关。甲基化也与甘油三酯和 HDL-C 的变化有关。此外，平均甲基化和甲基化分别解释了ΔTC（总胆固醇）变化的 7.2%和ΔHDL-C 水平变化的 17.5%。基因中的 DNA 甲基化对辛伐他汀降脂治疗有显著的抑制作用。
